WO2007053725A3 - Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties - Google Patents

Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties Download PDF

Info

Publication number
WO2007053725A3
WO2007053725A3 PCT/US2006/042753 US2006042753W WO2007053725A3 WO 2007053725 A3 WO2007053725 A3 WO 2007053725A3 US 2006042753 W US2006042753 W US 2006042753W WO 2007053725 A3 WO2007053725 A3 WO 2007053725A3
Authority
WO
WIPO (PCT)
Prior art keywords
novel
benzodiazepine
diones
therapeutic properties
methods
Prior art date
Application number
PCT/US2006/042753
Other languages
French (fr)
Other versions
WO2007053725A2 (en
Inventor
Gary D Glick
Original Assignee
Univ Michigan
Gary D Glick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan, Gary D Glick filed Critical Univ Michigan
Priority to NZ568254A priority Critical patent/NZ568254A/en
Priority to AU2006308655A priority patent/AU2006308655B2/en
Priority to JP2008539013A priority patent/JP5241501B2/en
Priority to CA2628193A priority patent/CA2628193C/en
Priority to EP06844249A priority patent/EP1948191B1/en
Publication of WO2007053725A2 publication Critical patent/WO2007053725A2/en
Publication of WO2007053725A3 publication Critical patent/WO2007053725A3/en
Priority to IL191175A priority patent/IL191175A/en
Priority to AU2010241505A priority patent/AU2010241505A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides novel 1,4- benzodiazepine-2,5-dione compounds, and methods of using novel l,4-benzodiazepine-2,5-dione compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, hyperproliferation, and the like.
PCT/US2006/042753 2005-11-01 2006-11-01 Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties WO2007053725A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
NZ568254A NZ568254A (en) 2005-11-01 2006-11-01 1,4-Benzodiazepine-2,5-diones for regulating cell death and treating autoimmune diseases
AU2006308655A AU2006308655B2 (en) 2005-11-01 2006-11-01 Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
JP2008539013A JP5241501B2 (en) 2005-11-01 2006-11-01 Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
CA2628193A CA2628193C (en) 2005-11-01 2006-11-01 Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
EP06844249A EP1948191B1 (en) 2005-11-01 2006-11-01 Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
IL191175A IL191175A (en) 2005-11-01 2008-04-30 1h- and 1-methyl-3,4-dihydro-2,5-dioxo-3-(pyrid-4-yl-p-phenylmethyl)-4h-l,4-benzodiazepine halosubstituted derivatives, pharmaceutical compositions comprising them and methods for regulating cell death using them
AU2010241505A AU2010241505A1 (en) 2005-11-01 2010-11-18 Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73204505P 2005-11-01 2005-11-01
US60/732,045 2005-11-01

Publications (2)

Publication Number Publication Date
WO2007053725A2 WO2007053725A2 (en) 2007-05-10
WO2007053725A3 true WO2007053725A3 (en) 2007-07-19

Family

ID=38006506

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/042753 WO2007053725A2 (en) 2005-11-01 2006-11-01 Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties

Country Status (8)

Country Link
US (3) US8088759B2 (en)
EP (2) EP1948191B1 (en)
JP (1) JP5241501B2 (en)
AU (2) AU2006308655B2 (en)
CA (2) CA2779041A1 (en)
IL (1) IL191175A (en)
NZ (1) NZ568254A (en)
WO (1) WO2007053725A2 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759338B2 (en) 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
US7851465B2 (en) 2007-03-09 2010-12-14 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US7994313B2 (en) 2005-06-01 2011-08-09 The Regents Of The University Of Michigan Unsolvated benzodiazepine compositions and methods
US8088759B2 (en) 2005-11-01 2012-01-03 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones with therapeutic properties
US8097612B2 (en) 2006-06-09 2012-01-17 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US8188072B2 (en) 2007-11-06 2012-05-29 The Regents Of The University Of Michigan Benzodiazepinone compounds useful in the treatment of skin conditions
US8324258B2 (en) 2007-09-14 2012-12-04 The Regents Of The University Of Michigan F1F0-ATPase inhibitors and related methods
US8497307B2 (en) 2008-09-11 2013-07-30 The Regents Of The University Of Michigan Aryl guanidine F1F0-ATPase inhibitors and related methods
US8604023B2 (en) 2009-04-17 2013-12-10 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
US8673897B2 (en) 2009-09-18 2014-03-18 The Regents Of The University Of Michigan Benzodiazepinone compounds and methods of treatment using same
US8809323B2 (en) 1999-04-30 2014-08-19 The Regents Of The University Of Michigan Therapeutic applications of pro-apoptotic benzodiazepines
US8815845B2 (en) 2009-11-17 2014-08-26 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
US9126978B2 (en) 2009-11-17 2015-09-08 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008528448A (en) 2005-01-03 2008-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Compositions and methods relating to novel compounds and targets thereof
JP5791595B2 (en) 2009-05-22 2015-10-07 アッヴィ・インコーポレイテッド Modulator of 5-HT receptor and method of use thereof
CA2800161C (en) 2010-05-21 2017-12-12 Abbvie Inc. Modulators of 5-ht receptors and methods of use thereof
DK2900230T3 (en) 2012-09-27 2018-11-12 Childrens Medical Ct Corp RELATIONSHIPS FOR TREATING ADIPOSITAS AND PROCEDURES FOR USING THEREOF
CN103435562B (en) * 2013-08-26 2016-02-24 华东理工大学 6-replaces Benzodiazepine-2,4-cyclohexadione compounds and uses thereof
CN105693634B (en) * 2016-03-17 2018-12-11 清华大学 Compound and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999067220A1 (en) * 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2457405A (en) 1945-09-25 1948-12-28 Monsanto Chemicals Halo nitroparaffin modified aminoplasts
DE1810423U (en) 1960-01-05 1960-04-28 Kaiserslautern Guss Armatur CHIMNEY CLEANING PLUG.
US3374264A (en) 1962-10-04 1968-03-19 Hoffmann La Roche N-haloacetyl-anthranilic acids and esters
US3261828A (en) 1962-10-04 1966-07-19 Hoffmann La Roche 3h-1,4-benzodiazepine-2,5(1h,4h)-dione compounds
US3384635A (en) 1966-09-28 1968-05-21 Sterling Drug Inc 1, 4-benzodiazepine derivatives
US3415814A (en) 1966-09-28 1968-12-10 Sterling Drug Inc 4-(cyclopropylmethyl)-3h-1,4-benzodiazepine-2,5(1h,4h)-dione
AT280290B (en) 1967-11-24 1970-04-10 Boehringer Sohn Ingelheim Process for the preparation of new 1-phenyl-4-alkyl-3H-1,4-benzodiazepine-2,5- [1H, 4H] -diones
USRE30293E (en) 1969-03-18 1980-06-03 Knoll A.G. Process for preparing 1,5-benzodiazepine-2-ones
US4108852A (en) 1969-03-18 1978-08-22 Knoll Ag. Process for preparing 1,5-benzodiazepine-2-ones
CH559729A5 (en) 1970-10-23 1975-03-14 Hoechst Ag
GB1324469A (en) 1970-10-28 1973-07-25 Knoll Ag Derivatives of benzodiazepines
ZA7467B (en) 1973-01-16 1974-11-27 J Voorhees Compositions and treatment of proliferative skin diseases with b2 agonists
IE38931B1 (en) 1973-03-09 1978-07-05 Lipha Triazolobenzodiazepines
US4076823A (en) 1977-08-18 1978-02-28 E. R. Squibb & Sons, Inc. Triazolo-2,4-benzodiazepines
JPS59112984A (en) 1982-12-21 1984-06-29 Shionogi & Co Ltd 1,4-benzodiazepine derivative
US4495101A (en) 1983-04-28 1985-01-22 American Home Products Corporation Antiinflammatory 5H-tetrazolo (5,1-c)(1,4)benzodiazepine derivatives
US4551480A (en) 1983-06-21 1985-11-05 Stiefel Laboratories, Inc. Compositions for the treatment of psoriasis
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US4820834A (en) 1984-06-26 1989-04-11 Merck & Co., Inc. Benzodiazepine analogs
US5004741A (en) 1984-06-26 1991-04-02 Merck & Co., Inc. Methods of antagonizing CCK or gastrin with benzodiazepine analogs
DE3435974A1 (en) 1984-10-01 1986-04-10 Boehringer Ingelheim KG, 6507 Ingelheim PHARMACEUTICAL COMPOSITIONS CONTAINING DIAZEPINE WITH PAF-ANTAGONISTIC EFFECT
FR2591596B1 (en) 1985-12-13 1988-09-09 Roussel Uclaf NOVEL 4H-TRIAZOLO (4,3-A) (1,4) BENZODIAZEPINES, THEIR PREPARATION PROCESS, THEIR APPLICATION AS MEDICAMENTS AND THE COMPOSITIONS CONTAINING THEM
GB8608080D0 (en) 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4751223A (en) 1986-10-14 1988-06-14 Hoechst-Roussel Pharmaceuticals, Inc. Antiinflammatory and analgesic aminoalkyl tetracyclic benzodiazepines
US4898861A (en) 1987-03-26 1990-02-06 Hoffmann-La Roche Inc. Method for inhibiting the proliferation of tumor cells
US5147872A (en) 1987-06-09 1992-09-15 Golwyn Daniel H Treatment of immunologically based disorders, specifically psoriasis
US4970207A (en) 1988-07-07 1990-11-13 Fujisawa Pharmaceutical Company, Ltd. Benzodiazepine derivatives
US5258510A (en) 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
US5041438A (en) 1989-10-30 1991-08-20 Hoffmann-La Roche Inc. Method for treating retroviral infections with benzodiazepine compounds
US5324726A (en) 1989-12-18 1994-06-28 Merck & Co., Inc. Benzodiazepine analogs
ATE145208T1 (en) 1990-07-06 1996-11-15 Yoshitomi Pharmaceutical CONDENSED THIOPHENE COMPOUNDS AND THEIR USE
BR9200951A (en) 1991-03-21 1992-11-17 Hoffmann La Roche COMPOUNDS, PROCESS FOR ITS PRODUCTION, PHARMACEUTICAL PREPARATIONS AND USE
CA2130195A1 (en) 1992-03-16 1993-09-30 Mark Gary Bock Benzodiazepine derivatives, compositions containing them and their use in therapy
US5599352A (en) 1992-03-19 1997-02-04 Medtronic, Inc. Method of making a drug eluting stent
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
GB9307527D0 (en) 1993-04-13 1993-06-02 Fujisawa Pharmaceutical Co New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
US5391566A (en) 1993-07-20 1995-02-21 Merck & Co., Inc. Benzimidazolinones substituted with phenoxyphenylacetic acid derivatives
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US5444092A (en) 1994-07-20 1995-08-22 Collins; Jerry Method and composition for treating psoriasis
JPH10504545A (en) 1994-07-29 1998-05-06 藤沢薬品工業株式会社 Benzodiazepine derivatives
CA2195973A1 (en) 1994-08-18 1996-02-29 David A. Claremon N-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1h-1,4-benzodiazepines
US5618792A (en) 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase
WO1996036361A1 (en) 1995-05-18 1996-11-21 The Regents Of The University Of Michigan Dna binding antibodies
US5677282A (en) 1995-06-07 1997-10-14 Proscript, Inc. Amino acid amides of 1,3,4-thiadiazoles as matrix metalloproteinase
US5692337A (en) * 1995-06-07 1997-12-02 Motz, Jr.; Ronald W. Collapsible plant shelter
US5962337A (en) 1995-06-29 1999-10-05 Pharmacopeia, Inc. Combinatorial 1,4-benzodiazepin-2,5-dione library
EP0850238A4 (en) * 1995-06-29 1998-10-07 Pharmacopeia Inc Combinatorial 1,4-benzodiazepin-2,5-dione library
RU2096044C1 (en) 1995-07-19 1997-11-20 Малое предприятие "Ветта" Veterinary implantable preparation for regulation of biological rhythm in animals
US5776946A (en) 1995-08-28 1998-07-07 Mcgeer; Patrick L. Peripheral benzodiazepine receptor ligands as antiinflammatory agents
EP0861092A4 (en) 1995-08-30 2002-04-10 Univ California Therapy for cellular accumulation in chronic inflammatory diseases
DE69619711T2 (en) 1995-09-21 2002-10-17 Inst Med Molecular Design Inc RETINOID POTENTIAL CONNECTIONS
US6579854B1 (en) 1996-08-14 2003-06-17 Vanderbilt University Diagnosis and management of infection caused by chlamydia
US7351421B2 (en) 1996-11-05 2008-04-01 Hsing-Wen Sung Drug-eluting stent having collagen drug carrier chemically treated with genipin
CN1130351C (en) 1996-12-10 2003-12-10 泽里新药工业株式会社 1,5-benzodiazepine derivatives
US6074859A (en) 1997-07-08 2000-06-13 Kikkoman Corporation Mutant-type bioluminescent protein, and process for producing the mutant-type bioluminescent protein
US6080568A (en) 1997-08-19 2000-06-27 Genencor International, Inc. Mutant α-amylase comprising modification at residues corresponding to A210, H405 and/or T412 in Bacillus licheniformis
US6635642B1 (en) * 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
BR9811716A (en) 1997-10-08 2000-07-18 Isotechnika Inc Deuterated cyclosporine analogs and their use as immune modulating agents
US6100254A (en) 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
EP1054871A2 (en) * 1998-04-01 2000-11-29 Du Pont Pharmaceuticals Company Pyrimidines and triazines as integrin antagonists
US6206914B1 (en) 1998-04-30 2001-03-27 Medtronic, Inc. Implantable system with drug-eluting cells for on-demand local drug delivery
FR2779963A1 (en) 1998-06-22 1999-12-24 Centre Nat Rech Scient New composition useful for treat cancer, comprises compound with affinity for mitochondrial benzodiazepine receptors and agent to induce apoptosis
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US20030044776A1 (en) 1998-09-25 2003-03-06 James A. Dykens Compositions and methods for identifying agents that alter mitochondrial permeability transition pores
FR2785803B1 (en) 1998-11-17 2005-03-25 Sanofi Sa USE OF A SUBSTANCE BINDING TO THE PERIPHERAL RECEPTOR OF BENZODIAZEPINES IN THE TREATMENT OF SKIN STRESS
US7175953B2 (en) 1999-04-09 2007-02-13 Institute Fuer Diagnostik Forschung Short-warp peptide-dye conjugate as contrast agent for optical diagnostic
US20060025388A1 (en) 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
US7276348B2 (en) 1999-04-30 2007-10-02 Regents Of The University Of Michigan Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof
US20050113460A1 (en) 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20040176358A1 (en) 1999-04-30 2004-09-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20030119029A1 (en) 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
ES2214273T3 (en) 1999-04-30 2004-09-16 The Regents Of The University Of Michigan USE OF BENZODIAZEPINS FOR THE TREATMENT OF AUTOIMMUNE DISEASES INDUCED BY APOPTOSIS.
US7572788B2 (en) 1999-04-30 2009-08-11 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
WO2001004103A1 (en) 1999-07-13 2001-01-18 F. Hoffmann-La Roche Ag Benzazepinones and quinazolines
US6524623B1 (en) 1999-11-12 2003-02-25 Milton Hodosh Therapeutic compositions and methods of use thereof
AU2001255709A1 (en) 2000-05-11 2001-11-20 Eastman Chemical Company Acylated cyclodextrin guest inclusion complexes
US20020048566A1 (en) 2000-09-14 2002-04-25 El-Deiry Wafik S. Modulation of cellular apoptosis and methods for treating cancer
CA2432825A1 (en) 2000-12-15 2002-06-20 Emory University Nonpeptide agonists and antagonists of vasopressin receptors
US7250410B2 (en) 2001-06-07 2007-07-31 Via Pharmaceuticals, Inc. Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof
MXPA04001421A (en) 2001-08-15 2004-06-03 Univ Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof.
BR0214048A (en) * 2001-11-13 2004-10-13 Dimensional Pharm Inc Substituted 1,4-benzodiazepines and their uses for cancer treatment
US6916813B2 (en) 2001-12-10 2005-07-12 Bristol-Myers Squibb Co. (1-phenyl-2-heteoaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase
WO2003106628A2 (en) 2002-06-17 2003-12-24 Bristol-Myers Squibb Company Benzodiazepine inhibitors of mitochondial f1f0 atp hydrolase and methods of inhibiting f1f0 atp hydrolase
US7150433B2 (en) 2002-08-16 2006-12-19 Toyota Motor Sales, U.S.A., Inc. Aircraft bolster trays
WO2004043362A2 (en) 2002-11-06 2004-05-27 Bristol-Myers Squibb Company Acyl guanidine compounds and use thereof
US20040087489A1 (en) 2002-11-06 2004-05-06 Antonio Ruiz Compositions and methods for the treatment of mycobacterial infections
EP1567161A4 (en) 2002-12-03 2008-09-03 Vela Acquisition Corp Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5h-2,3-benzodiazepine and uses thereof
JP2006509014A (en) 2002-12-04 2006-03-16 ジーン ロジック インコーポレイテッド Modulator of melanocortin receptor
CA2524394C (en) 2003-05-01 2011-07-12 The Regents Of The University Of Michigan Novel benzodiazepine compounds, compositions and uses thereof
US7351241B2 (en) 2003-06-02 2008-04-01 Carl Zeiss Meditec Ag Method and apparatus for precision working of material
US20090275099A1 (en) 2004-04-27 2009-11-05 Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20050272723A1 (en) 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
AU2005262322B2 (en) 2004-07-01 2012-07-26 Synta Pharmaceuticals Corp. 2-substituted heteroaryl compounds
US9071196B2 (en) 2004-07-06 2015-06-30 Qiuting Huang Double balanced mixer with switching pairs complementary to each other
US20060052369A1 (en) 2004-09-07 2006-03-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
WO2006053193A2 (en) 2004-11-10 2006-05-18 Garden Guardian, Inc. A device and method for controlling animal behavior
JP2008528448A (en) 2005-01-03 2008-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Compositions and methods relating to novel compounds and targets thereof
WO2007053193A2 (en) 2005-06-01 2007-05-10 The Regents Of The University Of Michigan Unsolvated benzodiazepine compositions and methods
EP1742460A1 (en) 2005-06-18 2007-01-10 TTE Germany GmbH Raster distortion correction circuit
US20070105844A1 (en) 2005-10-26 2007-05-10 Regents Of The University Of Michigan Therapeutic compositions and methods
WO2007050587A2 (en) 2005-10-26 2007-05-03 The Regents Of The University Of Michigan Therapeutic compositions and methods
WO2007053725A2 (en) 2005-11-01 2007-05-10 The Regents Of The University Of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
US7759338B2 (en) 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
EP2418206A3 (en) 2006-06-09 2012-06-27 The Regents of the University of Michigan Benzodiazepine derivatives useful in the treatment of autoimmune disorders
GB0615068D0 (en) 2006-07-28 2006-09-06 Ttp Communications Ltd Digital radio systems
MX2009009645A (en) 2007-03-09 2009-11-19 Univ Michigan Compositions and methods relating to novel compounds and targets thereof.
MX2010002732A (en) 2007-09-14 2010-06-02 Univ Michigan F1f0-atpase inhibitors and related methods.
UA99839C2 (en) 2007-11-06 2012-10-10 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Benzodiazepinone compounds useful in the treatment of skin conditions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999067220A1 (en) * 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DESJARDINS P. ET AL.: "The Role of Apoptosis in Neurodegenerative Disease", METABOLIC BRAIN DISEASE, vol. 13, no. 2, pages 79 - 96, XP003015636 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8809323B2 (en) 1999-04-30 2014-08-19 The Regents Of The University Of Michigan Therapeutic applications of pro-apoptotic benzodiazepines
US7994313B2 (en) 2005-06-01 2011-08-09 The Regents Of The University Of Michigan Unsolvated benzodiazepine compositions and methods
US8791104B2 (en) 2005-11-01 2014-07-29 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones with therapeutic properties
US8088759B2 (en) 2005-11-01 2012-01-03 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones with therapeutic properties
US7759338B2 (en) 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
US8097612B2 (en) 2006-06-09 2012-01-17 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US7851465B2 (en) 2007-03-09 2010-12-14 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US8242109B2 (en) 2007-03-09 2012-08-14 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US8324258B2 (en) 2007-09-14 2012-12-04 The Regents Of The University Of Michigan F1F0-ATPase inhibitors and related methods
US8461153B2 (en) 2007-11-06 2013-06-11 The Regents Of The University Of Michigan Benzodiazepinone compounds useful in the treatment of skin conditions
US8759340B2 (en) 2007-11-06 2014-06-24 The Regents Of The University Of Michigan Benzodiazepinone compounds useful in the treatment of skin conditions
US8188072B2 (en) 2007-11-06 2012-05-29 The Regents Of The University Of Michigan Benzodiazepinone compounds useful in the treatment of skin conditions
US8497307B2 (en) 2008-09-11 2013-07-30 The Regents Of The University Of Michigan Aryl guanidine F1F0-ATPase inhibitors and related methods
US8604023B2 (en) 2009-04-17 2013-12-10 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
US8673897B2 (en) 2009-09-18 2014-03-18 The Regents Of The University Of Michigan Benzodiazepinone compounds and methods of treatment using same
US8815845B2 (en) 2009-11-17 2014-08-26 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
US9126978B2 (en) 2009-11-17 2015-09-08 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties

Also Published As

Publication number Publication date
US20130261110A1 (en) 2013-10-03
EP2604269B1 (en) 2014-09-24
US8791104B2 (en) 2014-07-29
CA2779041A1 (en) 2007-05-10
NZ568254A (en) 2011-06-30
IL191175A (en) 2015-01-29
EP1948191A4 (en) 2011-01-05
IL191175A0 (en) 2009-02-11
WO2007053725A2 (en) 2007-05-10
JP2009513718A (en) 2009-04-02
AU2006308655A1 (en) 2007-05-10
JP5241501B2 (en) 2013-07-17
CA2628193A1 (en) 2007-05-10
AU2010241505A1 (en) 2010-12-09
EP1948191B1 (en) 2013-01-16
EP1948191A2 (en) 2008-07-30
US20120088757A1 (en) 2012-04-12
CA2628193C (en) 2012-08-14
EP2604269A1 (en) 2013-06-19
US8088759B2 (en) 2012-01-03
AU2006308655B2 (en) 2010-09-23
US20070111994A1 (en) 2007-05-17

Similar Documents

Publication Publication Date Title
WO2007053725A3 (en) Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
WO2006029245A3 (en) Compositions and methods relating to novel compounds and targets thereof
WO2006014526A3 (en) Compositions and methods relating to novel compounds and targets thereof
WO2008116156A3 (en) Methods and compositions for treating diseases and conditions associated with mitochondrial function
MX2009009645A (en) Compositions and methods relating to novel compounds and targets thereof.
WO2005004988A3 (en) Compositions and methods relating to novel compounds and targets thereof
WO2007050587A3 (en) Therapeutic compositions and methods
WO2003015703A3 (en) Compositions and methods relating to novel benzodiazepine compounds and targets thereof
MX2009005174A (en) 5-sulfanylmethyl-[1,2,4] triazol[1, 5-a] pyrimidin-7-ol derivatives as cxcr2 antagonists.
EP1507529B8 (en) Combination comprising valsartan, amlodipine and hydrochlorothiazide
WO2005074598A3 (en) Nitroxyl progenitor compounds and methods of use
MX2009005358A (en) 5-sulfanylmethyl-pyrazolo [1,5-a] pyrimidin-7-ol derivatives as cxcr2 antagonists.
EP2520311A3 (en) Method of treating hemolytic disease
WO2007126841A3 (en) Inhibition of alpha-synuclein toxicity
SI1725561T1 (en) 5,6-dialkyl-7-amino-triazolopyrimidines, method for their production, their use for controlling pathogenic fungi and agents containing said compounds
WO2005115439A3 (en) Cerberus/coco derivatives and uses thereof
WO2005075450A3 (en) Spiro-benzodioxoles and their use as cb1 antagonists
WO2004112719A8 (en) Chemical compounds
WO2009070485A8 (en) DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-α]IMIDAZOLE-3- CARBOXYLIC ACID AMIDES
TW200738608A (en) Organic compounds
WO2008089201A3 (en) Heterocyclic-substituted piperidine as orl-1 ligands
WO2006066950A3 (en) Tricyclic aminoalcohols, methods for producing the same and their use as anti-inflammatory agents
WO2005033048A3 (en) Wnt pathway antagonists
WO2006125181A3 (en) Piperidine derivatives and their use as stearoyl-coa desaturase modulators
WO2007009701A3 (en) Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2008539013

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/005644

Country of ref document: MX

Ref document number: 191175

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2628193

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 568254

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2006308655

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006844249

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006308655

Country of ref document: AU

Date of ref document: 20061101

Kind code of ref document: A